Upload
marilyn-munday
View
221
Download
0
Tags:
Embed Size (px)
Citation preview
Kai Pinkernell, MD4th Int. Symp. Stem Cell Therapy & CV Biology
Madrid, Spain26th of April 2007
Adipose Derived Stem Cell Therapy in Cardiovascular Disease.
AdipogenicOsteogenic ChondrogenicNeurogenic
Adipose Tissue Derived Stem Cells- The Concept
GalC AP Oil Red-O Alcian Blue
Zuk et al. Microbiology of the Cell 2003Zuk et al. Tissue Engineering 2001
- Easily accessible- Large amounts available
Liposuction ofAdipose Tissue
How to Obtain Adipose Derived Cells?
Washing media
Liquid fat
Collagen/Adipocytes/Debris
Cell pellet/erythrocytes
Adipose Derived Cells after Enzyme Digestion +
Centrifugation
Right picture from Tulane University
• Adipocytes
• Adult stem cells
• Endothelial cells
• Vasc. smooth muscle cells
• Fibroblasts
• Pericytes
• ……..
Adipose Derived Regenerative Cells (ADRCs)
Unique Population of Regenerative Cells
• Adipocytes
• Adult stem cells
• Endothelial cells
• Vasc. smooth muscle cells
• Fibroblasts
• Pericytes
• ……..
Adipose Tissue
How do ADRCs compare to other cell sources?
Cultured Adipose and Bone Marrow - CD Comparison
ADSC
MSC
ADSC
MSC
CD29
CD29
CD44
CD44
CD71
CD71
CD90
CD90
CD45
CD45
CD31
CD31CD105
CD105 SH3
SH3
CD34
CD34
Expression of Cell Surface Markers – Comparing ADSCs vs. BMCs
Fraser et al. Nat Med Clin Prac CV Med 2006;3,Suppl 1:S33-7
Expression of Cell Surface Markers –ADSCs Over Time in Culture
Fraser et al. Nat Med Clin Prac CV Med 2006;3,Suppl 1:S33-7
0
20
40
60
80
100
120
CD 34 CD 45 CD 11b CD 105Epitope
Perc
ent
24 hours 120 hours
* *<1%
*none
detected
CD34bright : 56.5% CD31bright : 6.8%
‘Fresh’ ADRCs CD Marker Expression
Representative of freshly isolated ADRCs; analysis using FACSDiva
Alfonso et al.
Proposed Mechanisms for ADCs –
Angiogenesis
ADRCs (top row) in a tube formation assay using Antibodies against CD31(red), von-Willebrandt factor (vWF, green) and DAPI (blue) as a nuclear stain. Fibroblasts (bottom row) were used as a control.
‘Fresh’ ADCs Tubule Formation
ADRC
Fibro-blasts
Angiogenesis: ADRC Participate in Vessel Formation
CD31
SMA
Von VIII
SMM
M. ZuhGel Plug (0.1 mL, 0.5 Mio.) of RosaLacZ ADRCs into collagen gel (no growth factors) in SCID mice, 3 weeks later.
Angiogenic Potential of ADCs
Miranville et al. Circ 2004; 110;349-355
Mouse Hindlimb Ischemia Model
24 hour ischemia, then i.v. infusion of 0.5 Mio human cells; murine athymics
Miranville et al. Circ 2004; 110;349-355
Plasticity of Human Adipose Lineage Cells Toward Endothelial Cells
Planat-Benard, et al., Circulation (2004)
CD31 CD31
Proposed Mechanisms for ADCs –
Differentiation
IHC – cardiac Troponin-T
100 m
day 20
Proposed Mechanisms – Paracrine Effects
Paracrine Factor Release
Rehmann et al. Circ.2004;109:1292-1298
Paracrine Factor Release
Rehmann et al. Circ.2004;109:1292-1298
Anti-Apoptotic Effect – in vivo
0
2
4
6
8
10
12
14
Saline ADC treatedAp
op
toti
c C
ard
iac
Myo
cyte
s/H
igh
Po
wer
F
ield
p < 0.01
TUNEL positive cells, 48 hours post AMI induction in rats.
In vivo PRE-Clinical Work- Hindlimb Ischemia
In vivo PRE-Clinical Work- Cardiac functional
39
4244
41
3735
0
10
20
30
40
50
60
AMI 4 wk 8 wk
[%]
55
3835
55
3943
0
10
20
30
40
50
60
70
Baseline AMI 8 weeks
[%]
Control
ADC
Porcine AMI Model - Tulane
*p=0.023
*
**p=0.037
**
Angiographic LVEF Perfusion (Cardiolite®)
• 16 pigs, 3 hour LAD infarction• Immediate Delivery of 1.5 Mio cells/kg
Porcine AMI Model - UCLA
30
35
40
45
50
55
60
Post-MI 6 Month
Eje
ctio
n F
ract
ion
%
Control
Cell Infusion
40
45
50
55
60
Post-MI 6 Month
Eje
ctio
n F
ract
ion
%
Control
Cell Infusion
Trans-thoracic Echocardiography Cineangiography
p=0.01 p=0.16
• 13 pigs, 1 hour LAD infarction• Delayed Delivery of 40-140 Mio cells at 48 hours
Watanabe et al. Am J Cardiol 2004; 94(suppl 6A):188E.
Rat AMI Model (UCLA)
Echocardiographic Dobutamine Responsiveness LVEF (Tip Catheter)
60
70
80
90
Pre 12 wk
[%]
SalineADCs
p<0.05
0
4000
8000
12000
16000
20000
baseline 3ng 6ng 15ng 30ng
Dobutamine Levels
Pre
ssu
re [
mm
Hg
]
p<0.05 for all levels of dobutamine challange
Strem et al. Circ, 2005; 112(17)
In vivo PRE-Clinical Work- Cardiac structural
Porcine AMI Model – Cultured ADSCs
Control ratio: 0.48 Adipose Cell ratio: 0.77
Control ADC - treated
Tulane University
Wall thickness infarcted myocardium / wall thickness healthy myocardium
0,58
0,750,69
0,00
0,20
0,40
0,60
0,80
1,00
sham ftMSC bmMSC
ns
ns
p < 0,02
Tulane University
Control ADC BMC
Porcine AMI Model – Cultured ADSCsLV Wallthickness
0
5
10
15
20
Infarct Area Border Zone Myocard
Wa
ll T
hic
kn
es
s [
mm
]
Control
ADC
Porcine AMI Model – Fresh ADRCsLV Wallthickness
(*p<0.05)
*
*
In vivo PRE-Clinical Work- Cardiac structural (histology)
Immunohistochemistry
• Persistence of labeled, transplanted Cells for 4, 8, 12 weeks and longer
• Co-staining with– Endothelial Markers– Smooth muscle cells markers– Low positivity with cardiac markers
Increase in Capillary Density
Tulane University
200x
630x
Porcine AMI Model – Cultured ADSCs
Box-Plot
Control ADC BMC
Tulane University
0
20
40
60
80
100
120
140
Infarct area Border Zone Myocardium
[co
un
ts/0
.1 m
m2
]
Control
ADC
Porcine AMI Model – Fresh ADRCs
(*p<0.05)*
Summary of Benefits of ADCs in Cardiovascular Diseases
Hindlimb Models• Increase in perfusion
Cardiac Disease Models• No arrhythmias or other cell related
mortality/morbidity• Improvement in function• Increased perfusion• Increased wall thickness
Cardiac Clinical Trials
Objective:
• Safety and feasibility in patients with non-revascularizable ischemia
• Center: Universitario Gregorio Marañon in Madrid, PI’s Fernandez-Avilés and Perin (Texas Heart Institute)
Trial design & inclusion:
• ADRCs delivered by intramyocardial injection via NOGA™
• Prospective, randomized, placebo-controlled, double-blind, dose escalation trial
• Measures to include ejection fraction, perfusion, max vO2, & 6-minute walk
• Up to 36 patients
• 6 month follow up
• Currently enrolling
PRECISE: Chronic Myocardial Ischemia Trial
Objective:
• Safety and feasibility in STEMI patients
• Center: Thoraxcenter, Erasmus University Rotterdam, PI Patrick Serruys
Proposed trial design & inclusion:
• Intra-coronary delivery of ADRCs
• Prospective, randomized, placebo-controlled, double-blind, dose escalation trial
• Measures to include ejection fraction, perfusion & wall motion
• Up to 48 patients
• 6-month follow-up
• Begin enrolling Q2 2007
APOLLO: Acute Myocardial Infarction Trial